

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CARsgen Therapeutics Holdings Limited**

**科濟藥業控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2171)**

### **VOLUNTARY ANNOUNCEMENT SHAREHOLDING INCREASE BY THE SUBSTANTIAL SHAREHOLDER AND SHARE REPURCHASE BY THE COMPANY**

This announcement is made by CARsgen Therapeutics Holdings Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**” or “**CARsgen**”) on a voluntary basis.

#### **Shareholding Increase by a Substantial Shareholder of the Company**

Reference is made to the announcement of the Company on December 18, 2023 (the “**Announcement**”). As disclosed in the Announcement, the board (the “**Board**”) of directors (the “**Director(s)**”) of the Company was informed by YIJIE Biotech Holding Limited (“**YIJIE Biotech**”), a substantial shareholder of the Company, that YIJIE Biotech and parties acting in concert with it (collectively “**YIJIE Concert Group**”) intended to acquire the shares of the Company (the “**Shares**”) from the open market within about twelve months from the date of the Announcement.

The Board has recently been informed by YIJIE Biotech that YIJIE Concert Group has purchased an aggregate number of 1,903,500 Shares within this year up to June 25 (after the market close), 2024, representing approximately 0.33% of the total issued Shares (the “**Shareholding Increase**”).

Before the Shareholding Increase, YIJIE Concert Group were interested in an aggregate of 215,572,730 Shares, representing approximately 37.45% of the total issued Shares. After the Shareholding Increase, YIJIE Concert Group holds 217,476,230 Shares, representing approximately 37.78% of the total issued Shares.

The Board considers that the Shareholding Increase indicates the substantial shareholder’s full confidence in the prospect and potential of growth of the Company and the recognition of the Company’s long-term investment value.

## Share Repurchase by the Company

As approved by the shareholders on the annual general meeting held on May 21, 2024, the Company could repurchase up to 10% of the total issued Shares as at the date of passing of such ordinary resolution, being a maximum of 57,564,391 Shares (the “**Repurchase Mandate**”). As of the market close on June 25, 2024, the Company has repurchased an aggregate number of 3,985,500 Shares, representing approximately 0.69% of the total issued Shares (the “**Share Repurchase**”). The funds used for the Share Repurchase come from non-IPO raised funds, which include, among others, business development (BD) income, interest income, and other subsidy. The Share Repurchase was made in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and all applicable laws and regulations to which the Company is subject.

The Company may, under the premise of meeting compliance requirements and from the perspective of maintaining the Company’s market value, make further repurchases of Shares. The Company has no present intention to repurchase the Shares to the extent that will trigger the obligations under The Hong Kong Code on Takeovers and Mergers.

By order of the Board  
**CARsgen Therapeutics Holdings Limited**  
**Dr. Zonghai LI**  
*Chairman*

Hong Kong, June 27, 2024

*As at the date of this announcement, the board of directors of the Company comprises Dr. Zonghai LI, Dr. Huamao WANG and Dr. Hua JIANG as executive Directors; Mr. Bingsen GUO, Mr. Huaqing GUO and Mr. Ronggang XIE as non-executive Directors; Dr. Guangmei YAN, Ms. Xiangke ZHAO and Dr. Wen ZHOU as the independent non-executive Directors.*

*In the case of inconsistency, the English text of this announcement shall prevail over the Chinese text.*